Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia

Psychiatry Research

Volumn 127, Issue 1-2, 2004, Pages 1-7

  Matsumoto, Chima ^a   Shinkai, Takahiro ^a   Hori, Hiroko ^a   Ohmori, Osamu ^a,b   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b Wakato Hospital   (Japan)

Author keywords

Catechol O methyltransferase; Genetic association; Monoamine oxidase A; Monoamine oxidase B; Polymorphism; Schizophrenia; Tardive dyskinesia

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; CATECHOL METHYLTRANSFERASE; CATECHOLAMINE; HALOPERIDOL; METHIONINE; NEUROLEPTIC AGENT; VALINE;

ADULT; AGED; ARTICLE; CODON; DISEASE PREDISPOSITION; ENZYME DEGRADATION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; INTRON; INVOLUNTARY MOVEMENT; JAPAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; TARDIVE DYSKINESIA;

ANTIPSYCHOTIC AGENTS; CATECHOL O-METHYLTRANSFERASE; CODON; DNA PRIMERS; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; MONOAMINE OXIDASE; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; RNA STABILITY; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 3142777760     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2004.03.011     Document Type: Article

References (31)

1. Andreassen O.A., Jorgensen H.A. Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats: implications for tardive dyskinesia? Progress in Neurobiology. 61:2000;525-541
2. Balciuniene J., Emilsson L., Oreland L., Pettersson U., Jazin E.E. Investigation of the functional effect of monoamine oxidase polymorphisms in human brain. Human Genetics. 110:2002;1-7
3. Boulton A.A., Eisenhofer G. Catecholamine metabolism: from molecular understanding to clinical diagnosis and treatment. Advances in Pharmacology. 42:1998;273-292
4. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. Journal of Clinical Psychiatry. 61:(Suppl 4):2000;5-9
5. Chakos M.H., Lieberman J.A., Bilder R.M., Borenstein M., Lerner G., Bogerts B., Wu H., Kinon B., Ashtari M. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs. American Journal of Psychiatry. 151:1994;1430-1436
6. 2 receptor gene and tardive dyskinesia in schizophrenia. Biological Psychiatry. 41:1997;827-829
7. Chong S.A., Tan E.C., Tan C.H., Mythily, Chan Y.H. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. American Journal of Medical Genetetics. 116B:2003;51-54
8. Corson P.W., Nopoulos P., Miller D.D., Arndt S., Andreasen N.C. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical vs. atypical neuroleptics. American Journal of Psychiatry. 156:1999;1200-1204
9. Deckert J., Catalano M., Syagailo Y.V., Bosi M., Okladnova O., Bella D.D., Nöthen M.M., Maffei P., Franke P., Fritze J., Maier W., Propping P., Beckmann H., Bellodi L., Lesch K.P. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Human Molecular Genetics. 8:1999;621-624
10. Egan M.F., Apud J., Wyatt R.J. Treatment of tardive dyskinesia. Schizophrenia Bulletin. 23:1997;583-609
11. Garpenstrand H., Ekblom J., Forslund K., Rylander G., Oreland L. Platelet monoamine oxidase activity is related to MAOB intron 13 genotype. Journal of Neural Transmission. 107:2000;523-530
12. Gerlach J., Casey D.E. Tardive dyskinesia. Acta Psychiatrica Scandinavica. 77:1988;369-378
13. Glazer W.M. Extrapyramidal side effects, tardive dyskinessia, and the concept of atypicality. Journal of Clinical Psychiatry. 61:(Suppl 3):2000;16-21
14. Guy W. Abnormal Involuntary Movement Scale (AIMS). ECDEU Assessment Manual for Psychopharmacology, Revised. 1976;534-537 US DREW publication, Department of Health, Education and Welfare, Washington, DC
15. Herken H., Erdal M.E., Boke O., Savas H.A. Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-O-methyltransferase gene. European Psychiatry. 18:2003;77-81
16. Hoda F., Nicoll D., Bennett P., Arranz M., Aitchison K.J., Al-Chalabhi A., Kunugi H., Vallada H., Leigh P.N., Chaudhuri K.R., Collier D.A. No association between Parkinson's disease and low-activity alleles of catechol O-methyltransferase. Biochemical and Biophysical Research Communications. 228:1996;780-784
17. 2 receptor gene and tardive dyskinesia in schizophrenia. Americal Journal of Medical Genetics. 105:2001;774-778
18. Hsu Y.P.P., Powell J.F., Sims K.B., Breakefield X.O. Molecular genetics of monoamine oxidase. Journal of Neurochemistry. 53:1989;12-18
19. Inada T., Dobashi I., Sugita T., Inagaki A., Kitao Y., Matsuda G., Kato S., Takano T., Yagi G., Asai M. Search for susceptibility locus to tardive dyskinesia. Human Psychopharmacology. 12:1997;35-39
20. 2 receptor gene and schizophrenia in Japanese subjects: replication and evaluation for antipsychotic-related features. International Journal of Neuropsychopharmacology. 2:1999;181-186
21. 2 receptor polymorphisms in patients with schizophrenia. Molecular Psychiatry. 7:2002;695-705
22. Klawans H.L., Goetz C.G., Perlik S. Tardive dyskinesia: review and update. American Journal of Psychiatry. 137:1980;900-908
23. Lachman H.M., Papolos D.F., Saito T., Yu Y.M., Szumlanski C.L., Weinshilboum R.M. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics. 6:1996;243-250
24. Norton N., Kirov G., Zammit S., Jones G., Jones S., Owen R., Krawczak M., Williams N.M., O'Donovan M.C., Owen M.J. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. American Journal of Medical Genetics. 114:2002;491-496
25. Schooler N.R., Kane J.M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry. 39:1982;486-487
26. Sham P.C., Curtis D. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci. Annals of Human Genetics. 59:1995;97-105
27. Shale H., Tanner C. Pharmacological options for the management of dyskinesias. Drugs. 52:1996;849-860
28. Sobol S.Z., Hu S., Hamer D. A functional polymorphism in the monoamine oxidase A gene promoter. Human Genetics. 103:1998;273-279
29. Tarsy D., Baldessarini R.J. The pathophysiologic basis of tardive dyskinesia. Biological Psychiatry. 12:1977;431-450
30. Toru M. Seishinbunnretsubyo no Yakuri [Pharmacology in Schizophrenia]. 1983;Chu-gai Igakusha Co, Tokyo
31. Winqvist R., Lundström K., Salminen M., Laatikainen M., Ulmanen I. The human catechol-O-methyltransferase (COMT) gene maps to band q11.2 of chromosome 22 and shows a frequent RFLP with BglI. Cytogenetics and Cell Genetics. 59:1992;253-257